Join the Keratoconjunctivitis Sicca group to help and get support from people like you.
Keratoconjunctivitis Sicca News
Related terms: Dry Eye Disease, Keratitis Sicca, Dry Eye Syndrome
Self-Imposed Use Cessation Dates Tied to Ophthalmic Drop Waste
TUESDAY, July 16, 2024 – Self-imposed use cessation dates (SUCD) for multiuse eye drop bottles leads to significant drug waste and associated costs, according to a report published online July 1...
FDA Approves Vevye (cyclosporine) Ophthalmic Solution for the Treatment of the Signs and Symptoms of Dry Eye Disease
Heidelberg, Germany and Cambridge, MA, USA, June 8, 2023 – Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that the U.S. Food and D...
FDA Approves Miebo (perfluorohexyloctane) Ophthalmic Solution for the Treatment of the Signs and Symptoms of Dry Eye Disease
VAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)-- May 18, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people ...
FDA Medwatch Alert: Global Pharma Healthcare Issues Voluntary Nationwide Recall of Delsam Pharma Artificial Eye Ointment Due to Possible Microbial Contamination
February 23, 2023 -- Global Pharma Healthcare is voluntarily recalling Batch No. H29 of Artificial Eye Ointment, distributed by Delsam Pharma to the consumer level, due to possible microbial ...
FDA Approves Tyrvaya (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
PRINCETON, N.J., Oct. 18, 2021 /PRNewswire/ – Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that the U.S. Food and Drug Administration (FDA) has approved Tyrvaya (varenicline solution)...
FDA Approves Eysuvis (loteprednol etabonate) Ophthalmic Suspension for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 27, 2020-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative...
Sun Pharma Announces FDA Approval of Cequa (cyclosporine) Ophthalmic Solution to Treat Dry Eye Disease
MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE)-- August 16, 2018 – Sun Pharmaceutical Industries Ltd. (Reuters:SUN.BO, Bloomberg:SUNP IN, NSE:SUNPHARMA, BSE:524715, “Sun Pharma” and includes its su...
FDA Approves Xiidra (lifitegrast ophthalmic solution) for Dry Eye Disease
July 12, 2016 – The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra...